Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 8/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775965 | 0.83 | STS (0.34) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL8776086 | 0.82 | ESR1 (0.54) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL6257173 | 0.80 | ESR1 (0.40) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL6257864 | 0.80 | ESR1 (0.40) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL29198904 | 0.72 | STS (0.69) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL29198906 | 0.72 | STS (0.69) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL18927078 | 0.72 | STS (0.69) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL18919503 | 0.72 | STS (0.69) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL30057226 | 0.72 | STS (0.69) | STSESR1ESR2CYP3A4ABCB11 | |
| SCHEMBL8775974 | 0.71 | STS (0.43) | STSESR1ESR2CYP3A4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0719276-B1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | US HEALTH (US) | 1997-11-26 | — | — | EP | claimed |
| US-5554603-A | 11,17-DINITRATES; USE TO ACHIEVE ESTROGENIC EFFECT IN FEMALE MAMMALS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-09-10 | — | — | US | claimed |
| WO-1995007925-A1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-23 | — | — | WO | claimed |
| US-8222237-B2 | Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones | EVESTRA, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100137264-A1 | PROGESTATIONAL 3-(6,6-ETHYLENE-17B-HYDROXY-3-OXO-17A-PREGNA-4-ENE-17A-YL)PROPIONIC ACID G-LACTONES | EVESTRA, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20090269403-A1 | ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS | EVESTRA, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-0719276-B1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | US HEALTH (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5554603-A | 11,17-DINITRATES; USE TO ACHIEVE ESTROGENIC EFFECT IN FEMALE MAMMALS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1995007925-A1 | ORALLY ACTIVE DERIVATIVES OF 1,3,5(10)-ESTRATRIENE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137264-A1 | PROGESTATIONAL 3-(6,6-ETHYLENE-17B-HYDROXY-3-OXO-17A-PREGNA-4-ENE-17A-YL)PROPIONIC ACID G-LACTONES | HSD17B11, CYP17A1, NR3C2 | STS 337/4885ESR1 40/4885ESR2 32/4885 |
| US-20090269403-A1 | ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS | SHBG, CYP19A1, PGRMC2 | STS 462/4885ESR1 11/4885ESR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.